Children with genetic confirmation of Dravet syndrome a documented sodium channel voltage-gated type I alpha subunit SCN1A mutation or clinical confirmation of Dravet syndrome by two pediatric neurologist will be considered to have Dravet syndrome In order to enter the treatment protocol there will be documented treatment failure of at least two therapeutic anticonvulsants excluding Na channel blockers Anticonvulsants that are Na channel blockers such as carbamazepine and lamotrigine as known to provoke seizures in this patient population 